Highlights

  • Resonance Health (ASX:RHT) reported FY26 revenue of AUD 15.75 million, up 42%.
  • FY26 net profit after tax reached AUD 1.51 million, compared with a loss in FY25.
  • The company recorded AUD 14.28 million in customer cash receipts during FY26.
  • Cash totalled AUD 4.85 million at year-end, alongside AUD 2.53 million in bank debt.

Resonance Health Limited (ASX:RHT) provides diagnostic imaging software and clinical trial services, with activities spanning healthcare technology, contract research and trial-site operations. Its FY26 annual results, published in August 2026, reported higher revenue and a return to statutory profitability, while management identified the replacement of revenue from a major clinical trial as a near-term operational priority. At the time of writing on 19 October 2026, the shares were quoted at AUD 0.069, down 9.21% during the day’s trading session.

Company Business

The group operates through three complementary activities. Its medical imaging software business provides quantitative image-analysis tools used in healthcare and research. Its clinical research organisation undertakes services connected with pharmaceutical studies, while the TrialsWest network supports the delivery of clinical trials through investigator sites. These activities expose the business to both regulated medical technologies and the timing of pharmaceutical research programmes.

Its imaging portfolio includes FerriSmart, HepaFat-AI and LiverSmart, which use software-assisted analysis to assess particular characteristics in medical images. Commercial outcomes for these products depend on clinical demand, permitted uses, deployment by healthcare institutions and continued technical support. The clinical services divisions depend on contracted study work, recruitment activity and operational delivery across research sites.

Recent Development

The company’s August 2026 annual results confirmed that a major clinical trial involving metabolic dysfunction-associated steatohepatitis, or MASH, had completed patient recruitment. That represents an important delivery milestone, but it also changes the profile of contracted activity. With the recruitment phase completed, management stated that replacing the associated revenue is a key priority for FY27.

During 2026, the group continued work on a liver fibrosis assessment device. Management described this programme as being under development and funded from operating cash flow. It did not include revenue from the product in its near-term planning. The company also appointed Dr David Fuller and Michael Sistenich to its board during the year, adding experience relevant to pharmaceutical development and healthcare investment.

In September 2026, Resonance Health announced a global strategic alliance and master services agreement with Image Analysis Group. The development added to its disclosed commercial initiatives, although the financial contribution of individual agreements should be assessed through subsequent reporting rather than assumed in advance.

Financial Performance and Sector Context

For the financial year ended 30 June 2026, group revenue increased by 42% to AUD 15,751,909. Net profit after tax was AUD 1,513,109, reversing the preceding year’s loss. The company reported that the profit improvement represented a turnaround exceeding AUD 3.3 million. Normalised EBITDA reached AUD 2.55 million, compared with an original FY26 management target of AUD 2.0 million.

Cash receipts from customers were AUD 14,280,910 for FY26. Management reported positive operating cash flow in each quarter. At 30 June 2026, cash holdings stood at AUD 4,849,447 and bank borrowings totalled AUD 2,533,334. The difference between those two balances was approximately AUD 2.32 million, although cash and debt alone do not represent a complete assessment of liquidity or other obligations.

Diagnostic imaging software operates in a sector subject to medical-device regulation, clinical validation requirements and procurement processes. Clinical trial services are also affected by pharmaceutical research budgets, patient recruitment schedules, protocol requirements and customer concentration. These factors can influence revenue recognition and staffing needs even where underlying scientific or service capabilities remain unchanged.

Risks to Consider

The completion of patient recruitment for the major MASH trial creates a revenue-replacement challenge. New studies may commence at different times or contribute at different margins. Medical imaging software faces implementation, validation and regulatory requirements, while development work on the liver fibrosis device may require further expenditure before commercial adoption can be established.

Financing also merits attention. The group disclosed an AUD 2,533,334 National Australia Bank facility maturing in March 2027 and stated that the board was working on renewal. Refinancing terms, changes in operating cash flows and investment in product development could affect the group’s financial flexibility.

What to Watch Next

Future disclosures may clarify the value and timing of new clinical trial contracts, the TrialsWest network’s activity levels and uptake of imaging software. Investors may also monitor the commercial implications of the September alliance, progress on the liver fibrosis programme and any update on the bank facility ahead of its March 2027 maturity.

The next periodic financial releases will provide a basis for assessing whether revenue generated by new studies and software services offsets the completion of existing trial activity. Cash conversion, profitability and research spending will also help describe the operating mix during FY27.

Key Insights

Resonance Health entered FY27 following a year of revenue growth, reported profitability and positive quarterly operating cash flow. However, the changing stage of a major trial and an approaching debt maturity introduce identifiable monitoring points. Subsequent company disclosures will determine how new contracts, product development and funding arrangements alter the financial profile.